Literature DB >> 23912341

Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms.

Joshua A Regal1, Todd A Festerling, Jeffrey M Buis, David O Ferguson.   

Abstract

DNA double-strand breaks (DSBs) can lead to instability of the genome if not repaired correctly. The MRE11/RAD50/NBS1 (MRN) complex binds DSBs and initiates damage-induced signaling cascades via activation of the ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia- and rad3-related (ATR) kinases. Mutations throughout MRE11 cause ataxia-telangiectasia-like disorder (ATLD) featuring cerebellar degeneration, and cancer-predisposition in certain kindreds. Here, we have examined the impact on DNA damage signaling of several disease-associated MRE11A alleles to gain greater understanding of the mechanisms underlying the diverse disease sequelae of ATLD. To this end, we have designed a system whereby endogenous wild-type Mre11a is conditionally deleted and disease-associated MRE11 mutants are stably expressed at physiologic levels. We find that mutations in the highly conserved N-terminal domain impact ATM signaling by perturbing both MRE11 interaction with NBS1 and MRE11 homodimerization. In contrast, an inherited allele in the MRE11 C-terminus maintains MRN interactions and ATM/ATR kinase activation. These findings reveal that ATLD patients have reduced ATM activation resulting from at least two distinct mechanisms: (i) N-terminal mutations destabilize MRN interactions, and (ii) mutation of the extreme C-terminus maintains interactions but leads to low levels of the complex. The N-terminal mutations were found in ATLD patients with childhood cancer; thus, our studies suggest a clinically relevant dichotomy in MRE11A alleles. More broadly, these studies underscore the importance of understanding specific effects of hypomorphic disease-associated mutations to achieve accurate prognosis and appropriate long-term medical surveillance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912341      PMCID: PMC3842175          DOI: 10.1093/hmg/ddt368

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  69 in total

1.  Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling.

Authors:  Moumita Chaki; Rannar Airik; Amiya K Ghosh; Rachel H Giles; Rui Chen; Gisela G Slaats; Hui Wang; Toby W Hurd; Weibin Zhou; Andrew Cluckey; Heon Yung Gee; Gokul Ramaswami; Chen-Jei Hong; Bruce A Hamilton; Igor Cervenka; Ranjani Sri Ganji; Vitezslav Bryja; Heleen H Arts; Jeroen van Reeuwijk; Machteld M Oud; Stef J F Letteboer; Ronald Roepman; Hervé Husson; Oxana Ibraghimov-Beskrovnaya; Takayuki Yasunaga; Gerd Walz; Lorraine Eley; John A Sayer; Bernhard Schermer; Max C Liebau; Thomas Benzing; Stephanie Le Corre; Iain Drummond; Sabine Janssen; Susan J Allen; Sivakumar Natarajan; John F O'Toole; Massimo Attanasio; Sophie Saunier; Corinne Antignac; Robert K Koenekoop; Huanan Ren; Irma Lopez; Ahmet Nayir; Corinne Stoetzel; Helene Dollfus; Rustin Massoudi; Joseph G Gleeson; Sharon P Andreoli; Dan G Doherty; Anna Lindstrad; Christelle Golzio; Nicholas Katsanis; Lars Pape; Emad B Abboud; Ali A Al-Rajhi; Richard A Lewis; Heymut Omran; Eva Y-H P Lee; Shaohui Wang; Joann M Sekiguchi; Rudel Saunders; Colin A Johnson; Elizabeth Garner; Katja Vanselow; Jens S Andersen; Joseph Shlomai; Gudrun Nurnberg; Peter Nurnberg; Shawn Levy; Agata Smogorzewska; Edgar A Otto; Friedhelm Hildebrandt
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

2.  The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response.

Authors:  J P Carney; R S Maser; H Olivares; E M Davis; M Le Beau; J R Yates; L Hays; W F Morgan; J H Petrini
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

3.  The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation.

Authors:  Zhenbao Yu; Gillian Vogel; Yan Coulombe; Danielle Dubeau; Elizabeth Spehalski; Josée Hébert; David O Ferguson; Jean Yves Masson; Stéphane Richard
Journal:  Cell Res       Date:  2011-08-09       Impact factor: 25.617

4.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

5.  The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks.

Authors:  T T Paull; M Gellert
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

6.  Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer.

Authors:  Kimberly A Zuhlke; Anna M Johnson; Linda A Okoth; Elena M Stoffel; Christiane M Robbins; Waibov A Tembe; Claudia A Salinas; S Lilly Zheng; Jianfeng Xu; John D Carpten; Ethan M Lange; William B Isaacs; Kathleen A Cooney
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

7.  Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation.

Authors:  A Van Hooser; D W Goodrich; C D Allis; B R Brinkley; M A Mancini
Journal:  J Cell Sci       Date:  1998-12       Impact factor: 5.285

8.  Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2.

Authors:  Jeffrey Buis; Trina Stoneham; Elizabeth Spehalski; David O Ferguson
Journal:  Nat Struct Mol Biol       Date:  2012-01-08       Impact factor: 15.369

9.  Structure of Mre11-Nbs1 complex yields insights into ataxia-telangiectasia-like disease mutations and DNA damage signaling.

Authors:  Christian B Schiller; Katja Lammens; Ilaria Guerini; Britta Coordes; Heidi Feldmann; Florian Schlauderer; Carolin Möckel; Alexandra Schele; Katja Strässer; Stephen P Jackson; Karl-Peter Hopfner
Journal:  Nat Struct Mol Biol       Date:  2012-06-17       Impact factor: 15.369

10.  Mre11 ATLD17/18 mutation retains Tel1/ATM activity but blocks DNA double-strand break repair.

Authors:  Oliver Limbo; Davide Moiani; Aryandi Kertokalio; Claire Wyman; John A Tainer; Paul Russell
Journal:  Nucleic Acids Res       Date:  2012-10-17       Impact factor: 16.971

View more
  28 in total

1.  Homozygous splice mutation in CWF19L1 in a Turkish family with recessive ataxia syndrome.

Authors:  Randi Burns; Karen Majczenko; Jishu Xu; Weiping Peng; Zuhal Yapici; James J Dowling; Jun Z Li; Margit Burmeister
Journal:  Neurology       Date:  2014-10-31       Impact factor: 9.910

2.  ATM directs DNA damage responses and proteostasis via genetically separable pathways.

Authors:  Ji-Hoon Lee; Michael R Mand; Chung-Hsuan Kao; Yi Zhou; Seung W Ryu; Alicia L Richards; Joshua J Coon; Tanya T Paull
Journal:  Sci Signal       Date:  2018-01-09       Impact factor: 8.192

3.  Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.

Authors:  Min Zhang; Guoyan Liu; Fengxia Xue; Robert Edwards; Anil K Sood; Wei Zhang; Da Yang
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

4.  MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress.

Authors:  Elizabeth Spehalski; Kayla M Capper; Cheryl J Smith; Mary J Morgan; Maria Dinkelmann; Jeffrey Buis; JoAnn M Sekiguchi; David O Ferguson
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

5.  Targeting Allostery with Avatars to Design Inhibitors Assessed by Cell Activity: Dissecting MRE11 Endo- and Exonuclease Activities.

Authors:  Davide Moiani; Daryl A Ronato; Chris A Brosey; Andrew S Arvai; Aleem Syed; Jean-Yves Masson; Elena Petricci; John A Tainer
Journal:  Methods Enzymol       Date:  2018-02-22       Impact factor: 1.600

6.  Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.

Authors:  Lawrence Leichman; Susan Groshen; Bert H O'Neil; Wells Messersmith; Jordan Berlin; Emily Chan; Cynthia G Leichman; Steven J Cohen; Deirdre Cohen; Heinz-Josef Lenz; Philip Gold; Bruce Boman; Anitra Fielding; Gershon Locker; Ronald C Cason; Stan R Hamilton; Howard S Hochster
Journal:  Oncologist       Date:  2016-01-19

Review 7.  Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?

Authors:  Haibo Wang; Prakash Dharmalingam; Velmarini Vasquez; Joy Mitra; Istvan Boldogh; K S Rao; Thomas A Kent; Sankar Mitra; Muralidhar L Hegde
Journal:  Mech Ageing Dev       Date:  2016-09-20       Impact factor: 5.432

8.  C-Terminal Binding Protein is Involved in Promoting to the Carcinogenesis of Human Glioma.

Authors:  Bo Liu; Gloria Di
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

9.  Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.

Authors:  Pia B Erben; Kathrin Brunner; Markus Hecht; Marlen Haderlein; Maike Büttner-Herold; Abbas Agaimy; Rainer Fietkau; Arndt Hartmann; Luitpold V Distel
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

10.  The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

Authors:  Yann Wallez; Charles R Dunlop; Timothy Isaac Johnson; Siang-Boon Koh; Chiara Fornari; James W T Yates; Sandra Bernaldo de Quirós Fernández; Alan Lau; Frances M Richards; Duncan I Jodrell
Journal:  Mol Cancer Ther       Date:  2018-06-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.